



Substitute for FORM 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number:	10/567766
Filing Date:	February 10, 2006
First Named Inventor:	HASEGAWA, Hideki
Group Art Unit:	1642
Confirmation Number:	5560
Examiner Name:	
Attorney Docket Number:	43512-103808

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
		Application or Patent Number	Kind Code				

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	B F	JP	2002516294		Loeb Health Research Institute at the Ottawa Hospital	Jun. 4, 2002		X ⁺

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	B G	Harandi et al., "Recent developments in mucosal immunomodulatory adjuvants," <i>Cur. Opin. Investigational Drugs</i> , 4(2): 156-161 (2003).		
	B H	Holmgren et al., "Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA," <i>Expert Rev. of Vaccines</i> , 2(2): 205-217 (2003).		
	B I	Jiang et al., "Poly(I·C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFκB and MAP kinase is through an interleukin-1 receptor-associate kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR," <i>J. Bio. Chem.</i> , 278(25): 16713-16719 (2003).		
	B J	Maeyama et al. "Effects of Recombinant Cholera Toxin B Subunit on IL-1β Production by Macrophages in Vitro," <i>Microbiol. Immunol.</i> , 46(9): 593-599 (2002).		
	B K	Tamura, "Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine," <i>Eur. J. Immunol.</i> , 22(2): 477-481 (1992).		
	B L	Wong et al., "Prophylactic and Therapeutic Efficacies of Poly (IC·LC) against Respiratory Influenza A virus Infection in Mice," <i>Antimicro. Agents and Chemotherapy</i> , 39(11): 2574-2576 (1995).		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AB/

CHDS01 SDEVADAS 463679v1

EXAMINER	/Agnieszka Boesen/	DATE CONSIDERED	05/10/2009
----------	--------------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).